



# Market Announcement

25 November 2019

---

## Recce Pharmaceuticals Ltd (ASX: RCE) – Trading Halt

### Description

The securities of Recce Pharmaceuticals Ltd ('RCE') will be placed in trading halt at the request of RCE, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 27 November 2019 or when the announcement is released to the market.

### Issued by

**Jessica Coupe**

Adviser, Listings Compliance (Perth)

25 November 2019

Ms Anjuli Sinniah  
Senior Adviser, Listings Compliance (Perth)  
Level 40 Central Park  
152 - 158 St George's Terrace  
PERTH WA 6000

By email: [tradinghaltsperth@asx.com.au](mailto:tradinghaltsperth@asx.com.au)

Dear Anjuli

**Recce Pharmaceuticals Ltd (ASX:RCE) – Trading halt request**


Pursuant to ASX Listing Rule 17.1, Recce Pharmaceuticals Ltd ACN 124 849 065 (**Company**) requests a trading halt of the Company's securities pending the release of an announcement relating to test results of the Company's product, RECCE® 327.

The Company requests that the trading halt be effective immediately and remain in place until the earlier of the commencement of normal trading on Wednesday 27 November 2019 or the release of an announcement by the Company in relation to the results.

The Company is not aware of any reason why the trading halt should not be granted.

For any questions, please contact the undersigned on +61 2 8072 1400.

Yours faithfully



Alistair McKeough  
Company Secretary



ASX: RCE

**Head Office** Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

**R&D Centre - Perth** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

**Washington Office** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA